How long before you see results from Wegovy

Step 1 — The first four weeks: your body adjusting, not yet transforming

Wegovy starts at 0.25mg, a dose chosen to let your system settle rather than deliver rapid weight loss. During these first four weeks, the medicine is establishing itself. Many people notice they feel full more quickly at meals, or that the pull towards snacking has quietly softened. The scales may barely move, and that is entirely normal.

The most common experiences in this early phase are gastrointestinal: nausea, occasional loose stools or constipation, or a general sense of queasiness after eating. These effects tend to be at their most noticeable now. Keeping meals small, eating slowly, and staying well-hydrated helps most people through them. The NHS medicines page for semaglutide has clear guidance on managing these early side effects.

One practical note: the pen lives in the fridge, so many people find it easiest to do their weekly injection on the same morning each week before leaving the house, it becomes a habit quickly. If you are curious about how long it takes to see results from Wegovy and what to expect at each stage, the short answer is that this first month is about settling in, not transforming. That is not failure; it is how the medicine is designed to work.

Step 2, Months two to four: dose increases and the first real weight shift

Your prescriber moves the dose upwards roughly every four weeks: from 0.25mg to 0.5mg, then 1.0mg, then 1.7mg. Each step typically brings a renewed appetite-suppressing effect, and this is the period when most people see their first consistent downward movement on the scales.

By the end of month three, weight loss of 3–5% of starting body weight is a reasonable expectation for people tolerating doses well, though the range is genuinely wide. Some people lose more, some less. The STEP 1 trial (which tracked nearly 1,961 adults over 68 weeks) found that even participants who ended up with the largest total losses showed a gradual, not sudden, trajectory during this phase. You can read more about what Wegovy results look like across the full treatment period to set realistic expectations before you start.

Gastrointestinal side effects often ease considerably by month two as your body adapts to each dose level. If they persist or feel unmanageable, that is a conversation to have with your prescriber before pushing the dose higher, not something to push through alone.

Step 3, Months four to six: reaching maintenance and the steeper curve

For most people on the standard titration schedule, the 2.4mg maintenance dose is reached around month five. This is where the STEP 1 trial data (published in the New England Journal of Medicine) is most relevant: average weight reduction of around 15% of body weight over the full 68 weeks, with the greatest monthly losses typically happening in this middle phase of treatment.

Concretely, for someone starting at 100kg, 15% represents 15kg. That figure is a trial average among people who reached the 2.4mg dose and stayed on treatment, individual outcomes sit on either side of it. If you are wondering how long before you see results on Wegovy and what the early milestones typically look like, the rate of loss tends to slow naturally as weight decreases, which is biology, not the medicine failing.

If you are curious about how Wegovy's mechanism translates into the rate of effect, the short version is that semaglutide acts on GLP-1 receptors to reduce appetite signalling and slow gastric emptying, meaning you feel full sooner and stay full longer, which reduces calorie intake gradually and sustainably rather than abruptly.

The full Wegovy treatment overview covers the licensed eligibility criteria and what a clinical assessment involves if you are weighing up whether to start.

What happens if progress stalls or stops?

Weight loss plateauing is common and expected, particularly in months eight to twelve. The body adapts. NICE guidance on semaglutide notes that if less than 5% weight loss has been achieved after six months on the maintenance dose, the prescriber should review whether continuing makes sense, that is a clinical conversation, not a reason to stop without advice. NICE's appraisal of semaglutide (TA875) sets out the full framework that informs prescribing decisions.

A plateau does not always mean the medicine has stopped working. Reassessing diet, activity levels and whether lifestyle changes have drifted back towards old patterns often reveals what has shifted. Reducing meal size, prioritising protein and maintaining some regular movement are the factors most consistently linked to sustained loss alongside GLP-1 treatment.

If you want to understand how long it takes to see results from Wegovy and why the pace varies from person to person, that page covers it in more depth. For questions specific to your own progress, our prescribers are the right people to ask. Start a free consultation and a GPhC-registered prescriber will review your case the same day.